NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis $0.42 +0.03 (+8.02%) As of 10:08 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Reviva Pharmaceuticals Stock (NASDAQ:RVPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Reviva Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.35▼$0.4250-Day Range$0.34▼$0.5452-Week Range$0.26▼$15.40Volume1,770 shsAverage Volume289,432 shsMarket Capitalization$5.51 millionP/E RatioN/ADividend YieldN/APrice Target$53.33Consensus RatingHold Company Overview Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system, inflammatory and cardiometabolic disorders. The company’s lead product candidate is brilaroxazine, formerly known as RP5063, a novel serotonin-dopamine activity modulator being developed for psychiatric and neurological conditions. Brilaroxazine has been evaluated in clinical studies for schizophrenia and has also been investigated for other potential indications, including bipolar disorder, major depressive disorder, dementia-related behavioral symptoms and pulmonary arterial hypertension. Reviva’s development strategy is based on the compound’s activity across multiple serotonin and dopamine receptors, although its safety and effectiveness for these uses remain subject to regulatory review and further clinical evaluation. Reviva was founded by Laxminarayan Bhat, Ph.D., who serves as the company’s president and chief executive officer. The company is headquartered in Cupertino, California, and conducts its research and clinical-development activities through collaborations and trials involving patients in the United States and other international markets.AI Generated. May Contain Errors. Read More Reviva Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreRVPH MarketRank™: 2.68035152151 of 5 starsReviva Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingReviva Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialReviva Pharmaceuticals has a consensus price target of $53.33, representing about 13,617.4% upside from its current price of $0.39.Amount of Analyst CoverageReviva Pharmaceuticals has received no research coverage in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($2.96) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reviva Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for RVPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment1.00 News SentimentReviva Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders8.90% of the stock of Reviva Pharmaceuticals is held by insiders.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVPH Stock News HeadlinesReviva Pharmaceuticals Reports FDA Feedback Timeline, New Brilaroxazine Patent Progress and Q3 2026 ResultsNovember 12 at 8:30 PM | quiverquant.comQReviva Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 12 at 8:13 PM | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 13 at 1:00 AM | Porter & Company (Ad)Reviva Pharmaceuticals (RVPH) Projected to Release Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comReviva Pharmaceuticals op Lytham Partners: brilaroxazine vordertSeptember 29, 2026 | nl.investing.comReviva Pharmaceuticals alla conferenza Lytham Partners: avanza brilaroxazineSeptember 29, 2026 | it.investing.comReviva to Participate in the Lytham Partners Fall 2026 Investor ConferenceSeptember 22, 2026 | globenewswire.comRVPH: Patent Filed for New FormulationAugust 17, 2026 | finance.yahoo.comSee More Headlines RVPH Stock Analysis - Frequently Asked Questions How have RVPH shares performed this year? Reviva Pharmaceuticals' stock was trading at $5.58 at the start of the year. Since then, RVPH stock has decreased by 93.0% and is now trading at $0.3888. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) released its earnings results on Thursday, August, 13th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.20. When did Reviva Pharmaceuticals' stock split? Reviva Pharmaceuticals shares reverse split on Monday, March 9th 2026.The 1-20 reverse split was announced on Thursday, March 5th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 6th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Reviva Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Immunic (IMUX), Pfizer (PFE), Rigetti Computing (RGTI), SoundHound AI (SOUN) and Archer Aviation (ACHR). Company Calendar Last Earnings8/13/2026Today11/13/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RVPH's financial health is in the Red zone, according to TradeSmith. RVPH has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RVPH Previous SymbolNASDAQ:TZAC CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees14Year Founded2006Price Target and Rating Average Price Target for Reviva Pharmaceuticals$53.33 High Price Target$80.00 Low Price Target$40.00 Potential Upside/Downside+12,598.4%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-391.58% Return on Assets-119.08% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book0.28Miscellaneous Outstanding Shares13,110,000Free Float11,670,000Market Cap$5.51 million OptionableNo Data Beta0.61 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:RVPH) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
